Get the Stockscreener App
309.66
3.27%
-10.47
After Hours:
310.05
0.39
+0.13%
Alnylam Pharmaceuticals Inc stock is traded at $309.66, with a volume of 1.50M.
It is down -3.27% in the last 24 hours and down -3.36% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
See More
Previous Close:
$320.13
Open:
$326.09
24h Volume:
1.50M
Relative Volume:
1.15
Market Cap:
$41.32B
Revenue:
$3.71B
Net Income/Loss:
$313.75M
P/E Ratio:
137.19
EPS:
2.2571
Net Cash Flow:
$465.38M
1W Performance:
-3.87%
1M Performance:
-3.36%
6M Performance:
-35.71%
1Y Performance:
+32.02%
1-Day Range:
$306.00
$326.53
1-Week Range:
$306.00
$343.36
52-Week Range:
$228.28
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN
JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN
GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple - Yahoo Finance
RNAi Technology Market to Reach USD 9.58 Billion by 2033 at 15.26% - openPR.com
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results - BioSpace
Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset - Quiver Quantitative
KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wells Fargo raises Alnylam (ALNY) revenue estimates for Amvuttra despite projected margin compression - MSN
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Eastern Progress
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Eastern Progress
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Eastern Progress
Did New Vutrisiran Data and FCF Breakeven Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st
Sumitomo Mitsui Trust Group Inc. Has $130.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Truist Financial Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $505.00 - MarketBeat
Whats the beta of Alnylam Pharmaceuticals Inc stockWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Trimmed by Baillie Gifford & Co. - MarketBeat
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference - Yahoo
Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock? - Insider Monkey
A Look At Alnylam Pharmaceuticals’ (ALNY) Valuation After Recent Mixed Share Price Performance - simplywall.st
10 Best Growth Stocks to Buy With Highest Upside Potential - Insider Monkey
Alnylam Achieves Leading Trading Position Despite Declining Volume as Revenue Surges - Bitget
ALNY (Alnylam Pharmaceuticals) Earnings Yield (Joel Greenblatt) % : 1.13% (As of Dec. 2025) - GuruFocus
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025 - Yahoo Finance
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $450 - Moomoo
Alnylam Cardiovascular Data Highlights Potential Upside In ATTR-CM And Hypertension - Yahoo Finance
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Trading Systems Reacting to (ALNY) Volatility - Stock Traders Daily
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million By Investing.com - Investing.com India
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million - Investing.com
Alnylam (NASDAQ: ALNY) HR chief auto-sells shares to cover RSU taxes - Stock Titan
Alnylam (NASDAQ: ALNY) HR chief details stock and option holdings - Stock Titan
Is the options market signaling a potential surge in Alnylam Pharmaceuticals shares? - Bitget
Book value per share of Alnylam Pharmaceuticals, Inc – LSE:0HD2 - TradingView
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap DownHere's What Happened - MarketBeat
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors - simplywall.st
Alnylam (NASDAQ: ALNY) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Options Chain - Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance UK
Porphyria Treatment Market to Reach US$ 358.64 Million by 2032 - openPR.com
[ARS] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):